Characterization of Protein Therapeutics using Mass Spectrometry
Produktdetaljer
Biographical note
GUODONG CHEN, PHD, has extensive pharmaceutical research experience in major pharmaceutical companies, including Eli Lilly and Company, Schering-Plough and Bristol-Myers Squibb. Currently, he heads the analytical/mass spectrometry group at Bristol-Myers Squibb’s Princeton site in support of drug discovery programs and development projects in small molecule pharmaceuticals and biologics. He has over 65 research publications in peer-reviewed journals and book chapters, and three edited/co-edited books in pharmaceutical analysis. His other contributions to the scientific community include over 80 presentations at scientific conferences and academic institutes; service as a short course instructor, as session chair at various scientific forums, and as a reviewer for journals. He received his Ph.D. in Analytical Chemistry from Purdue University under the direction of Professor R. Graham Cooks.
Protein therapeutics’ high efficacy, safety, and ability to treat life-threatening diseases such as cancer, inflammation and genetic disorders have revolutionized modern medicine. In 2012, 200 companies competed in this $90 billion year industry.
In Characterization of Protein Therapeutics using Mass Spectrometry, expert contributors from academia and industry highlight current approaches and future trends. The book discusses mass spectrometry techniques as related to the analysis of protein therapeutics, structural identification strategies and quantitative approaches. The book also covers various studies involving characterization of process related protein drug impurities/degradants, metabolites, PTMs and higher order structures of protein therapeutics.
General practitioners in pharmaceutical research, specialists in analytical sciences, and graduate students studying mass spectrometry and pharmaceutical sciences will find this book useful because of the step-by-step approaches and new strategies to solve challenging problems related to protein therapeutics research and development.
Produktdetaljer
Biographical note
GUODONG CHEN, PHD, has extensive pharmaceutical research experience in major pharmaceutical companies, including Eli Lilly and Company, Schering-Plough and Bristol-Myers Squibb. Currently, he heads the analytical/mass spectrometry group at Bristol-Myers Squibb’s Princeton site in support of drug discovery programs and development projects in small molecule pharmaceuticals and biologics. He has over 65 research publications in peer-reviewed journals and book chapters, and three edited/co-edited books in pharmaceutical analysis. His other contributions to the scientific community include over 80 presentations at scientific conferences and academic institutes; service as a short course instructor, as session chair at various scientific forums, and as a reviewer for journals. He received his Ph.D. in Analytical Chemistry from Purdue University under the direction of Professor R. Graham Cooks.